This is the first time Mr Dilip Shanghvi, founder of Sun Pharmaceutical has been named in the top three with a 66 percent surge in his wealth –

25 oct 2013

Singapore: For the first time, founder of leading Indian drugmaker Sun Pharmaceuticals, Mr Dilip Shanghvi has been named in the top three of India’s richest men. Mr Shanghvi has made an appearance in the list prepared by China based ‘Hurun India Rich List’ as the third richest Indian man with a 66 percent surge in his wealth. Energy tycoon and Reliance Industries chairman Mr Mukesh Ambani has topped the list as India’s richest man with personal assets of $18.9 billion, news reports mentioned. The report pointed out that Mr Ambani has retained the top position for the second year even after a wealth decrease of two percent. London-based steel baron Mr Lakshmi Narayan Mittal has been named the second richest, with assets of $15.9 billion. – See more at: http://www.biospectrumasia.com/biospectrum/news/199210/sun-pharma-s-founder-named-india-s-3rd-richest#.Umzu4fmnqls

Read more at: http://www.biospectrumasia.com/biospectrum/news/199210/sun-pharma-s-founder-named-india-s-3rd-richest#.Umzu4fmnql
s

Potential of US pipeline continues to be under appreciated

SUNP’s US pipeline is shaping up well, with an interesting mix of complex products, branded generics and me-too products. Motilal Oswal believe that SUNP’s strong pipeline in the US is well placed to deliver revenue CAGR of 25% to USD1.8b. While a meaningful contribution to this growth is being led by Doxil and recently acquired URL Pharma, we estimate that SUNP’s own pipeline is set to witness revenue CAGR of 40% to USD6 20m. They build flat sales growth for Taro as they expect incremental competition to impact the market share for key Taro products. If competition is delayed, their estimates may have room for positive surprise.

Even after a 50-plus per cent return in one year, Sun Pharma’s stock continues to hold promise. While domestic revenues are growing well, US sales growth has been phenomenal, driven by a strong product pipeline and the acquisitions of Taro, DUSA, URL generics and Caraco.

1. [PDF]

   NCE & NDDS Development Pipeline – Sun Pharma

   www.sunpharma.com/pressdownload.php?download_file=329.pdf‎

   NCE & NDDS Development Pipeline / 2. Disclaimer. Except for the historical information contained herein, statements in this presentation and the subsequent …

2. [PDF]

   Pipeline of Potential Ocular Therapies to Help Millions … – Sun Pharma

   www.sunpharma.com/pressdownload.php?…Press%20Release%20SunPh…‎

   Oct 1, 2013 – 1. For Immediate Release. Sun Pharma and Intrexon Form Joint Venture to Develop. New Class of Therapeutics for Ocular Diseases. Pipeline …

   

   pipeline

   Sun Pharma Advanced Research (SPARC, US$345
   mn market cap), a proprietary product research
   company, detailed its NDDS and NCE product pipelines
   in its latest filing with the SEBI, pursuant to its proposed
   rights issue. Overall, there has been modest
   clinical/regulatory progression in the NDDS pipeline
   since the last disclosure six-seven months back. See
   Exhibits 1 and 4 inside.
   Key highlights: Big picture – New Drug Delivery
   System (NDDS) – Overall SPARC is developing a
   diverse collection of seven technology platforms for oral,
   injectable and topical delivery systems (including nano
   particulate, bio-degradable depot, DPI, SMM, GFR).
   SPARC has 19 NDDS products under development.
   New Chemical Entity (NCE) – The company has a
   pipeline of five compounds that are pro-drugs of existing
   molecules (such as baclofen, gabapentin etc). The NCE
   pipeline appears to be in its early stages, with market
   launch a few years away.
   Update on key products (NDDS) – Three lead drugs:
   1) levetiracetam XR 1000/1500 mg (505(b)(2) filing with
   USFDA is now targeted for F1Q13), 2) baclofen GRS
   (Special Protocol Assessment, SPA, agreement has
   been received from FDA and patient enrollment for
   Phase 3 studies is targeted in F4Q12) and 3) BAK-free
   latanoprost (Phase III patient enrollment over in US).
   These timelines imply that the first product launch in the
   US is likely in 2H13. SPARC continues to validate its
   underlying technology platforms by launching drugs in
   the domestic market (six proprietary launches, seven
   generic launches so far).
   Other milestones for CY12: IND filing with USFDA for
   two drugs – Octreotide Depot Inj (1 month) and Dry
   Powder Inhaler (Salmeterol and Fluticasone
   combination); paclitaxel (with carboplatin) Phase I
   results in US and clinical progress of second WRAP
   based drug, cardiovascular agent (and its combination)

   NDDS

   LATANOPROST

   LATANOPROST+TIMOLOLOL

   BACLOFEN VENLAFAXINE

   LEVETIRACETAM

   PICN, PACLITAXEL

   NCE

   SUN597,

   SUN L731

   SUN K706

   OTHERS

   DRY POWDER INHALER

   DOCETAXEL NANODISPERSION

   OCTEOTIDE

   

   MAY 2013
   mn market cap), a proprietary product research
   company, detailed its NDDS and NCE product pipelines
   in its latest filing with the SEBI, pursuant to its proposed
   rights issue. Overall, there has been modest
   clinical/regulatory progression in the NDDS pipeline
   since the last disclosure six-seven months back. See
   Exhibits 1 and 4 inside.
   Key highlights: Big picture – New Drug Delivery
   System (NDDS) – Overall SPARC is developing a
   diverse collection of seven technology platforms for oral,
   injectable and topical delivery systems (including nano
   particulate, bio-degradable depot, DPI, SMM, GFR).
   SPARC has 19 NDDS products under development.
   New Chemical Entity (NCE) – The company has a
   pipeline of five compounds that are pro-drugs of existing
   molecules (such as baclofen, gabapentin etc). The NCE
   pipeline appears to be in its early stages, with market
   launch a few years away.
   Update on key products (NDDS) – Three lead drugs:
   1) levetiracetam XR 1000/1500 mg (505(b)(2) filing with
   USFDA is now targeted for F1Q13), 2) baclofen GRS
   (Special Protocol Assessment, SPA, agreement has
   been received from FDA and patient enrollment for
   Phase 3 studies is targeted in F4Q12) and 3) BAK-free
   latanoprost (Phase III patient enrollment over in US).
   These timelines imply that the first product launch in the
   US is likely in 2H13. SPARC continues to validate its
   underlying technology platforms by launching drugs in
   the domestic market (six proprietary launches, seven
   generic launches so far).
   Other milestones for CY12: IND filing with USFDA for
   two drugs – Octreotide Depot Inj (1 month) and Dry
   Powder Inhaler (Salmeterol and Fluticasone
   combination); paclitaxel (with carboplatin) Phase I
   results in US and clinical progress of second WRAP
   based drug, cardiovascular agent (and its combination)